- Dec 17, 2020
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
MCARH109 CART MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma This study will test the...
673
- Dec 17, 2020
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide
NCT04497961: Phase 2: A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide...
76
- Dec 12, 2020
NCT04093596: Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)
UNIVERSAL Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma...
405
- Dec 12, 2020
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma NCT04405167: Phase 1: Tasquinimod for the Treatment...
24
- Dec 12, 2020
NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis
CAEL-101 Amy NCT04512235: Phase 3: A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL...
303
- Dec 12, 2020
NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181
EQUATE TRIAL EAA181 / EQUATE Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE...
522